Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.
OBJECTIVE
A novel chemically modified heparin derivative, heparin-deoxycholic acid nano-particles, has lower anticoagulant activity, and was recently reported to have significant anti-tumor effects on squamous head and neck cancer cells. Therefore, the aim of this study was to evaluate the anti-tumor effects of heparin-deoxycholic acid nano-particles in a human lung adenocarcinoma cell line.


METHODS
An orthotopic lung cancer model in 16 mice was developed using intra-thoracic injections of 0.5x10(6) PC14PE6 cells. Ten days after inoculation, the mice were divided into two groups. PBS and Heparin-DOCA particles were injected once a day every 3 days in the tail vein, for a total of 5 injections. The body weight and survival of each mouse were monitored and the tumor size in the lung was measured by SPECT-CT before and after heparin-DOCA nano-particle treatment.


RESULTS
IThe HD particles had no significant cytotoxicity when the PC9 cells were treated in vitro. There was no statistical difference in tumor size, body weight and survival between the HD treated and control groups in vivo. Furthermore, there was no difference in the amount of CD31 between tumor tissues in the two study groups.


CONCLUSIONS
HD synthesized with unfractionated heparin had no apparent inhibitory effects on tumor growth in a PC14PE6 cell induced orthotopic lung cancer mouse model. The HD particles did not significantly inhibit tumor-induced angiogenesis at the tumor sites.
Cui
Zheng Yun
ZY
Medical Nanoelement Development Center, Seoul, Korea.
Park
Min Jae
MJ
Lee
Jeeyun
J
Ahn
Jin Seok
JS
Ahn
Myung Ju
MJ
Seo
Soo Won
SW
Park
Jin Woo
JW
Byun
Youngro
Y
Park
Keunchil
K
Clin Cancer Res. 2008 May 1;14(9):2841-9
18451252
Pharm Res. 2007 Jan;24(1):176-85
17109210
Crit Rev Oncol Hematol. 2007 Mar;61(3):195-207
17074500
J Clin Oncol. 2001 Jul 1;19(13):3210-8
11432888
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
Cancer Res Treat. 2006 Dec;38(4):234-9
19771249
Pharmacol Rev. 2001 Mar;53(1):93-105
11171940
Thromb Haemost. 2006 Mar;95(3):535-40
16525583
Int J Microcirc Clin Exp. 1996 Jan-Feb;16(1):8-15
8739219
Clin Exp Metastasis. 1999 Jul;17(5):451-6
10651313
J Clin Oncol. 2004 May 15;22(10):1944-8
15143088
J Clin Oncol. 2005 Apr 1;23(10):2123-9
15699480
Br J Cancer. 2002 Jun 5;86(11):1803-12
12087470
Cancer Res. 2002 Jul 1;62(13):3722-8
12097281
Cancer Res Treat. 2007 Dec;39(4):139-49
19746208
Biomaterials. 2007 Jun;28(16):2667-76
17335894
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7003-11
16203794
Langmuir. 2004 Dec 21;20(26):11726-31
15595804
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Clin Oncol. 2005 Apr 1;23(10):2130-5
15699479
J Clin Oncol. 2002 Nov 1;20(21):4285-91
12409326
J Control Release. 2006 Sep 12;114(3):300-6
16884806
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7
11248082
J Biol Chem. 2000 Aug 11;275(32):24653-60
10816596